Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)

Introduction: A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed EGFR-activating mutation allele count, increased total cell-free DNA (cfDNA) concentration, and shortened cfDNA fragment size with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) plus ERL...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kazuto Nishio, MD, PhD, Kazuko Sakai, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, PhD, Carla Visseren-Grul, MD, Michelle Carlsen, MS, Sotaro Enatsu, MD, PhD, Tomoko Matsui, BSc, RPh, Kazuhiko Nakagawa, MD, PhD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-05-01
Serie:	JTO Clinical and Research Reports
Soggetti:	Circulating tumor DNA Liquid biopsy EGFR-activating mutation alleles cfDNA fragments Carcinoma non–small cell lung
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666364326000147
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!